We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Crucell NV ADS, Each Representing One Ordinary Share (MM) | NASDAQ:CRXL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0 | - |
From Jun 2019 to Jun 2024
U.S. pharmaceuticals company Johnson & Johnson (JNJ) said Tuesday it completed the tender offer for Dutch biotechnology company Crucell NV (CRXL.AE) and has declared the offer unconditional.
MAIN FACTS:
- Johnson & Johnson declares the Offer for unconditional
- As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.
- Share Acceptance Level is 95.24% of the issued and outstanding share capital of Crucell
- Settlement of the Offer will take place on 25 February 2011
- Remaining Shares can be tendered in a Subsequent Offering Period ending 8 March 2011
- Johnson & Johnson intends to acquire the remaining Shares not tendered by means of buy-out proceedings in accordance with article 2:92a and/or 359c of the Dutch Civil Code, to be initiated as soon as reasonably practicable under applicable rules and regulations
- By Amsterdam Bureau, Dow Jones Newswires; amsterdam@dowjones.com
1 Year Crucell NV ADS, Each Representing One Ordinary Share (MM) Chart |
1 Month Crucell NV ADS, Each Representing One Ordinary Share (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
